Prenetics Global Ltd (NASDAQ: PRE)

Sector: Healthcare Industry: Diagnostics & Research CIK: 0001876431
P/B 1.20
P/E -4.16
P/S 2.92
Market Cap 193.77 Mn
ROIC (Qtr) -26.00
Div Yield % 0.00
Rev 1y % (Qtr) 567.69
Total Debt (Qtr) 2.11 Mn
Debt/Equity (Qtr) 0.01

About

Stock Price Chart

Analysis

Pros

  • Healthy cash reserves of 13.26M provide 9.30x coverage of short-term debt 1.43M, demonstrating strong liquidity position and minimal refinancing risk.
  • Strong tangible asset base of 188.14M provides 89.38x coverage of total debt 2.10M, indicating robust asset backing and low credit risk.
  • Tangible assets of 188.14M provide exceptional 26.11x coverage of deferred revenue 7.21M, showing strong service capability backing.
  • Long-term investments of 95.70M provide solid 140.95x coverage of long-term debt 679000, indicating strategic financial planning.
  • Retained earnings of 118.10M provide full 173.94x coverage of long-term debt 679000, indicating strong internal capital position.

Cons

  • Investment activities of 0 provide weak support for R&D spending of 6.97M, which is 0x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • Operating cash flow of 0 provides insufficient coverage of deferred revenue obligations of 7.21M, which is 0x, raising concerns about future service delivery capabilities.
  • Long-term investments of 95.70M represent a high 43.26x of fixed assets 2.21M, indicating potential overexposure to financial assets versus operational capabilities.
  • Operating cash flow of 0 provides minimal -0x coverage of tax expenses of (7.43M), suggesting potential tax planning inefficiencies or unsustainable tax positions.
  • R&D investment of 6.97M represents just 0.10x of SG&A expenses of 66.99M, indicating potential underinvestment in innovation relative to administrative overhead.

Peer Comparison

Companies in the Diagnostics & Research
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 TMO Thermo Fisher Scientific Inc. 216.83 Bn 33.00 4.96 35.68 Bn
2 DHR Danaher Corp /De/ 162.47 Bn 46.38 6.69 16.86 Bn
3 IDXX Idexx Laboratories Inc /De 56.88 Bn 55.36 13.65 1.09 Bn
4 A Agilent Technologies, Inc. 39.82 Bn 32.64 5.87 3.41 Bn
5 IQV Iqvia Holdings Inc. 38.85 Bn 30.28 2.44 15.19 Bn
6 NTRA Natera, Inc. 31.32 Bn -101.29 14.80 0.18 Bn
7 MTD Mettler Toledo International Inc/ 28.99 Bn 34.68 7.35 2.21 Bn
8 WAT Waters Corp /De/ 22.92 Bn 35.32 7.38 1.49 Bn

Industry Comparisons

Current Valuation

Metric Value Industry Percentile
EV to Assets 0.91 2.69
EV to Cash from Ops. -6.20 18.14
EV to Debt 85.08 52.51
EV to EBIT -3.32 19.22
EV to EBITDA -4.24 4.35
EV to Free Cash Flow [EV/FCF] -5.99 2.84
EV to Market Cap 0.92 1.52
EV to Revenue 2.70 4.79
Price to Book Value [P/B] 1.20 1.34
Price to Earnings [P/E] -4.16 22.02

Dividend Metrics

Metric Value Industry Percentile
Dividend Coverage Ratio 0.00 -1.96
Dividend Payout Ratio % 0.00 2.83
Dividend per Basic Share 0.00 0.19
FCF Dividend Payout Ratio % 0.00 1.92
Interest Coverage 0.00 -126.58

Growth Metrics

Metric Value Industry Percentile
Capex Growth (1y) % 0.00 -31.50
Cash and Equivalents Growth (1y) % -58.47 21.37
Dividend Growth (1y) % 0.00 0.24
EBIAT Growth (1y) % 0.76 -55.24
EBITDA Growth (1y) % 0.00 -447.96
EBIT Growth (1y) % -14.33 -40.50
EBT Growth (1y) % -14.33 -70.94
EPS Growth (1y) % 6.54 -70.02
FCF Growth (1y) % 0.00 56.33
Gross Profit Growth (1y) % 226.20 185.11

Liquidity Ratios

Metric Value Industry Percentile
Asset Utilization Ratio 0.34 0.56
Cash Payout Ratio 0.00 0.01
Cash Ratio 0.52 1.21
Current Ratio 1.51 2.64
Debt to Equity Ratio 0.01 -0.80
Interest Cover Ratio 0.00 -126.58
Times Interest Earned 0.00 -126.58

Profitability

Metric Value Industry Percentile
EBITDA Margin % 0.00 -129.91
EBIT Margin % -81.39 -156.71
EBT Margin % -81.39 -162.23
Gross Margin % 46.90 47.70
Net Profit Margin % -70.20 -189.30